Close Menu

NEW YORK – Japanese regulators have approved Daiichi Sankyo's trastuzumab deruxtecan (Enhertu), a HER2-targeted antibody drug conjugate, for chemotherapy-treated, unresectable or recurrent breast cancer patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.